Hillsdale Investment Management Inc. increased its position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 28.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 132,800 shares of the medical equipment provider’s stock after purchasing an additional 29,200 shares during the quarter. Hillsdale Investment Management Inc. owned 0.34% of Lantheus worth $3,758,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in Lantheus by 15.3% in the 4th quarter. Geode Capital Management LLC now owns 428,939 shares of the medical equipment provider’s stock valued at $6,712,000 after purchasing an additional 56,935 shares during the last quarter. Legal & General Group Plc increased its position in Lantheus by 0.9% in the 4th quarter. Legal & General Group Plc now owns 82,403 shares of the medical equipment provider’s stock valued at $1,272,000 after acquiring an additional 721 shares during the period. Millennium Management LLC acquired a new position in Lantheus in the 4th quarter valued at approximately $1,615,000. Dimensional Fund Advisors LP increased its position in Lantheus by 5.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,379,017 shares of the medical equipment provider’s stock valued at $21,581,000 after acquiring an additional 65,609 shares during the period. Finally, Meeder Asset Management Inc. increased its position in Lantheus by 212.8% in the 1st quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 3,236 shares during the period. 91.35% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Mary Anne Heino sold 16,827 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $23.89, for a total transaction of $401,997.03. Following the completion of the sale, the chief executive officer now directly owns 637,762 shares in the company, valued at $15,236,134.18. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Brian A. Markison sold 5,000 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.73, for a total transaction of $123,650.00. Following the sale, the director now owns 62,467 shares of the company’s stock, valued at $1,544,808.91. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 136,187 shares of company stock valued at $3,604,063. Corporate insiders own 2.60% of the company’s stock.
NASDAQ LNTH traded up $1.21 on Friday, hitting $23.10. The company’s stock had a trading volume of 384,700 shares, compared to its average volume of 497,467. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05. Lantheus Holdings Inc has a 1-year low of $12.59 and a 1-year high of $29.80. The company’s 50-day moving average is $25.64 and its 200 day moving average is $24.32. The firm has a market cap of $826.87 million, a PE ratio of 24.57, a PEG ratio of 1.68 and a beta of 1.47.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The firm had revenue of $85.70 million during the quarter, compared to analysts’ expectations of $88.72 million. During the same period in the prior year, the company posted $0.25 EPS. The company’s revenue was up .1% on a year-over-year basis. On average, equities analysts expect that Lantheus Holdings Inc will post 1.06 EPS for the current year.
LNTH has been the subject of several recent research reports. ValuEngine cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. CJS Securities upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research report on Friday. Zacks Investment Research cut shares of Lantheus from a “hold” rating to a “sell” rating in a research report on Friday, August 2nd. Finally, BidaskClub cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. Lantheus currently has an average rating of “Hold” and an average target price of $29.00.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Featured Story: Catch-Up Contributions
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.